A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis
Status:
Completed
Trial end date:
2018-02-28
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, double-blind, placebo- and tezacaftor/ivacaftor
(TEZ/IVA)-controlled, parallel-group, 3-part, multicenter study designed to evaluate the
safety and efficacy of VX-659 in triple combination (TC) with TEZ and IVA in subjects with
cystic fibrosis (CF) who are homozygous for the F508del mutation of the CF transmembrane
conductance regulator (CFTR) gene (F/F genotype), or who are heterozygous for the F508del
mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ, IVA, or
TEZ/IVA (F/MF genotypes).